ASTRAZENAstrazeneca Pharma India Ltd.
Astrazeneca Pharma India to launch Datverzo breast cancer drug in November
- Guidance
- Pharmaceuticals
Reviewed byKeshav SehgalBlacklitt Research
Astrazeneca Pharma India (NSE: ASTRAZEN) will launch Datverzo, the brand name of Datopotamab Deruxtecan, in India in November 2026, it said in a filing on 07 Nov 2026. The company had earlier reported receiving the import and market permission from the Drugs Controller General of India in December 2025.
The launch and its approval
Astrazeneca Pharma India Limited will launch Datverzo in India in November 2026. The company earlier intimated on 17 Dec 2025 that it had received Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Datopotamab Deruxtecan under the brand name Datverzo.
Datverzo is already approved for adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
The company in context
The launch is a product step in a company that reported total income of ₹744.22 crore for Q2 FY27 on a standalone basis, up 31.7% year on year. Its most recent filing before this one, dated 02 Nov 2026, was an intimation the company enclosed for reference.
What the Datverzo launch means for Astrazeneca Pharma India's shareholders
The filing confirms a launch in India in November 2026 of a drug already approved in the country. The filing does not say what the drug will sell for, the exact launch date within the month, or what effect the launch will have on the company's results.
At a glance
| Item | Detail |
|---|---|
| Product | Datverzo (Datopotamab Deruxtecan) |
| Approval | Import and Market Permission in Form CT-20, Drugs Controller General of India, intimated 17 Dec 2025 |
| Planned launch | November 2026 |
| Filing date | 07 Nov 2026 |
Filed with NSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
